# Biomarin Pharmaceutical Inc: financial statements, quarterly

BMRN · Nasdaq · CIK 1048477 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bmrn.md) · [Financials](/companies/bmrn/financials.md) · [Filings](/companies/bmrn/filings.md) · [Insiders](/companies/bmrn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bmrn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [581](/filings/0001048477-24-000152.md) | [646 d](/filings/0001048477-26-000004.md) | [649](/filings/0001048477-25-000051.md) | [712](/filings/0001048477-25-000090.md) | [746](/filings/0001048477-25-000107.md) | [747 d](/filings/0001048477-26-000004.md) | [745](/filings/0001048477-26-000008.md) | [825](/filings/0001048477-26-000016.md) | [776](/filings/0001048477-25-000107.md) | [875 d](/filings/0001048477-26-000004.md) | [766](/filings/0001048477-26-000008.md) | [990](/filings/0001048477-26-000016.md) |
| Cost of revenue | $m | [128](/filings/0001048477-24-000152.md) | [138 d](/filings/0001048477-26-000004.md) | [125](/filings/0001048477-25-000051.md) | [130](/filings/0001048477-25-000090.md) | [188](/filings/0001048477-25-000107.md) | [136 d](/filings/0001048477-26-000004.md) | [152](/filings/0001048477-26-000008.md) | [150](/filings/0001048477-26-000016.md) | [140](/filings/0001048477-25-000107.md) | [276 d](/filings/0001048477-26-000004.md) | [195](/filings/0001048477-26-000008.md) | [203](/filings/0001048477-26-000016.md) |
| Research and development | $m | [191](/filings/0001048477-24-000152.md) | [206 d](/filings/0001048477-26-000004.md) | [205](/filings/0001048477-25-000051.md) | [184](/filings/0001048477-25-000090.md) | [185](/filings/0001048477-25-000107.md) | [174 d](/filings/0001048477-26-000004.md) | [159](/filings/0001048477-26-000008.md) | [161](/filings/0001048477-26-000016.md) | [409](/filings/0001048477-25-000107.md) | [192 d](/filings/0001048477-26-000004.md) | [179](/filings/0001048477-26-000008.md) | [207](/filings/0001048477-26-000016.md) |
| Selling, general and administrative | $m | [216](/filings/0001048477-24-000152.md) | [260 d](/filings/0001048477-26-000004.md) | [226](/filings/0001048477-25-000051.md) | [263](/filings/0001048477-25-000090.md) | [253](/filings/0001048477-25-000107.md) | [267 d](/filings/0001048477-26-000004.md) | [206](/filings/0001048477-26-000008.md) | [232](/filings/0001048477-26-000016.md) | [268](/filings/0001048477-25-000107.md) | [446 d](/filings/0001048477-26-000004.md) | [258](/filings/0001048477-26-000008.md) | [396](/filings/0001048477-26-000016.md) |
| Operating income | $m | [30.5](/filings/0001048477-24-000152.md) | [27.3 d](/filings/0001048477-26-000004.md) | [88.5](/filings/0001048477-25-000051.md) | [120](/filings/0001048477-25-000090.md) | [114](/filings/0001048477-25-000107.md) | [161 d](/filings/0001048477-26-000004.md) | [224](/filings/0001048477-26-000008.md) | [277](/filings/0001048477-26-000016.md) | [(46.7)](/filings/0001048477-25-000107.md) | [(44.6) d](/filings/0001048477-26-000004.md) | [130](/filings/0001048477-26-000008.md) | [111](/filings/0001048477-26-000016.md) |
| Interest expense | $m | [3.8](/filings/0001048477-23-000044.md) | [6.1 d](/filings/0001048477-24-000016.md) | [3.5](/filings/0001048477-24-000070.md) | [3.6](/filings/0001048477-25-000090.md) | [3.0](/filings/0001048477-25-000107.md) | [2.6 d](/filings/0001048477-26-000004.md) | [2.4](/filings/0001048477-26-000008.md) | [2.4](/filings/0001048477-26-000016.md) | [2.6](/filings/0001048477-25-000107.md) | [2.8 d](/filings/0001048477-26-000004.md) | [9.6](/filings/0001048477-26-000008.md) | [60.7](/filings/0001048477-26-000016.md) |
| Income tax | $m | [1.3](/filings/0001048477-24-000152.md) | [(1.0) d](/filings/0001048477-26-000004.md) | [16.9](/filings/0001048477-25-000051.md) | [25.0](/filings/0001048477-25-000090.md) | [28.4](/filings/0001048477-25-000107.md) | [44.7 d](/filings/0001048477-26-000004.md) | [52.4](/filings/0001048477-26-000008.md) | [57.3](/filings/0001048477-26-000016.md) | [4.4](/filings/0001048477-25-000107.md) | [19.4 d](/filings/0001048477-26-000004.md) | [35.7](/filings/0001048477-26-000008.md) | [16.6](/filings/0001048477-26-000016.md) |
| Net income | $m | [40.4](/filings/0001048477-24-000152.md) | [20.4 d](/filings/0001048477-26-000004.md) | [88.7](/filings/0001048477-25-000051.md) | [107](/filings/0001048477-25-000090.md) | [106](/filings/0001048477-25-000107.md) | [125 d](/filings/0001048477-26-000004.md) | [186](/filings/0001048477-26-000008.md) | [241](/filings/0001048477-26-000016.md) | [(30.7)](/filings/0001048477-25-000107.md) | [(46.6) d](/filings/0001048477-26-000004.md) | [106](/filings/0001048477-26-000008.md) | [44.8](/filings/0001048477-26-000016.md) |
| Diluted EPS | $ per share | [0.21](/filings/0001048477-24-000152.md) | not reported | [0.46](/filings/0001048477-25-000051.md) | [0.55](/filings/0001048477-25-000090.md) | [0.55](/filings/0001048477-25-000107.md) | not reported | [0.95](/filings/0001048477-26-000008.md) | [1.23](/filings/0001048477-26-000016.md) | [(0.16)](/filings/0001048477-25-000107.md) | not reported | [0.54](/filings/0001048477-26-000008.md) | [0.23](/filings/0001048477-26-000016.md) |
| Basic EPS | $ per share | [0.21](/filings/0001048477-24-000152.md) | not reported | [0.47](/filings/0001048477-25-000051.md) | [0.56](/filings/0001048477-25-000090.md) | [0.56](/filings/0001048477-25-000107.md) | not reported | [0.97](/filings/0001048477-26-000008.md) | [1.25](/filings/0001048477-26-000016.md) | [(0.16)](/filings/0001048477-25-000107.md) | not reported | [0.55](/filings/0001048477-26-000008.md) | [0.23](/filings/0001048477-26-000016.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.8](/filings/0001048477-23-000044.md) | [0.8](/filings/0001048477-25-000007.md) | [0.7](/filings/0001048477-24-000070.md) | [1.0](/filings/0001048477-24-000126.md) | [0.7](/filings/0001048477-24-000152.md) | [0.9](/filings/0001048477-26-000004.md) | [1.0](/filings/0001048477-25-000051.md) | [1.2](/filings/0001048477-25-000090.md) | [1.3](/filings/0001048477-25-000107.md) | [1.3](/filings/0001048477-26-000016.md) | [2.2](/filings/0001048477-26-000008.md) | [0.9](/filings/0001048477-26-000016.md) |
| Current assets | $bn | [3.0](/filings/0001048477-23-000044.md) | [3.0](/filings/0001048477-25-000007.md) | [3.0](/filings/0001048477-24-000070.md) | [3.3](/filings/0001048477-24-000126.md) | [3.1](/filings/0001048477-24-000152.md) | [3.2](/filings/0001048477-26-000004.md) | [3.5](/filings/0001048477-25-000051.md) | [3.8](/filings/0001048477-25-000090.md) | [3.9](/filings/0001048477-25-000107.md) | [4.0](/filings/0001048477-26-000016.md) | [4.6](/filings/0001048477-26-000008.md) | [4.0](/filings/0001048477-26-000016.md) |
| Total assets | $bn | [6.8](/filings/0001048477-23-000044.md) | [6.8](/filings/0001048477-25-000007.md) | [6.9](/filings/0001048477-24-000070.md) | [7.1](/filings/0001048477-24-000126.md) | [6.9](/filings/0001048477-24-000152.md) | [7.0](/filings/0001048477-26-000004.md) | [7.1](/filings/0001048477-25-000051.md) | [7.5](/filings/0001048477-25-000090.md) | [7.6](/filings/0001048477-25-000107.md) | [7.6](/filings/0001048477-26-000016.md) | [8.6](/filings/0001048477-26-000008.md) | [11.7](/filings/0001048477-26-000016.md) |
| Current liabilities | $bn | [1.2](/filings/0001048477-23-000044.md) | [1.2](/filings/0001048477-25-000007.md) | [1.1](/filings/0001048477-24-000070.md) | [1.1](/filings/0001048477-24-000126.md) | [0.7](/filings/0001048477-24-000152.md) | [0.6](/filings/0001048477-26-000004.md) | [0.6](/filings/0001048477-25-000051.md) | [0.7](/filings/0001048477-25-000090.md) | [0.8](/filings/0001048477-25-000107.md) | [0.8](/filings/0001048477-26-000016.md) | [0.8](/filings/0001048477-26-000008.md) | [1.7](/filings/0001048477-26-000016.md) |
| Total liabilities | $bn | [1.9](/filings/0001048477-23-000044.md) | [1.9](/filings/0001048477-25-000007.md) | [1.8](/filings/0001048477-24-000070.md) | [1.8](/filings/0001048477-24-000126.md) | [1.4](/filings/0001048477-24-000152.md) | [1.3](/filings/0001048477-26-000004.md) | [1.4](/filings/0001048477-25-000051.md) | [1.4](/filings/0001048477-25-000090.md) | [1.6](/filings/0001048477-25-000107.md) | [1.5](/filings/0001048477-26-000016.md) | [2.4](/filings/0001048477-26-000008.md) | [5.4](/filings/0001048477-26-000016.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.6](/filings/0001048477-26-000016.md) | [1.4](/filings/0001048477-26-000008.md) | [3.5](/filings/0001048477-26-000016.md) |
| Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001048477-26-000016.md) | not reported | [0.7](/filings/0001048477-26-000016.md) |
| Shareholders' equity | $bn | [4.9](/filings/0001048477-24-000152.md) | [5.0](/filings/0001048477-26-000004.md) | [5.1](/filings/0001048477-25-000090.md) | [5.3](/filings/0001048477-25-000107.md) | [5.4](/filings/0001048477-25-000107.md) | [5.7](/filings/0001048477-26-000016.md) | [5.8](/filings/0001048477-26-000016.md) | [6.0](/filings/0001048477-26-000016.md) | [6.1](/filings/0001048477-25-000107.md) | [6.1](/filings/0001048477-26-000016.md) | [6.2](/filings/0001048477-26-000016.md) | [6.3](/filings/0001048477-26-000016.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [136 d](/filings/0001048477-24-000152.md) | [27.5 d](/filings/0001048477-26-000004.md) | [47.0](/filings/0001048477-25-000051.md) | [119 d](/filings/0001048477-25-000090.md) | [221 d](/filings/0001048477-25-000107.md) | [186 d](/filings/0001048477-26-000004.md) | [174](/filings/0001048477-26-000008.md) | [185 d](/filings/0001048477-26-000016.md) | [369 d](/filings/0001048477-25-000107.md) | [99.6 d](/filings/0001048477-26-000004.md) | [221](/filings/0001048477-26-000008.md) | [168 d](/filings/0001048477-26-000016.md) |
| Capital expenditure | $m | [21.7 d](/filings/0001048477-24-000152.md) | [28.9 d](/filings/0001048477-26-000004.md) | [26.1](/filings/0001048477-25-000051.md) | [21.3 d](/filings/0001048477-25-000090.md) | [18.5 d](/filings/0001048477-25-000107.md) | [19.5 d](/filings/0001048477-26-000004.md) | [16.8](/filings/0001048477-26-000008.md) | [17.1 d](/filings/0001048477-26-000016.md) | [28.4 d](/filings/0001048477-25-000107.md) | [40.7 d](/filings/0001048477-26-000004.md) | [20.9](/filings/0001048477-26-000008.md) | [28.8 d](/filings/0001048477-26-000016.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [186](/filings/0001048477-23-000044.md) | [194](/filings/0001048477-24-000070.md) | [195](/filings/0001048477-24-000126.md) | [191](/filings/0001048477-24-000152.md) | [199](/filings/0001048477-25-000051.md) | [201](/filings/0001048477-25-000090.md) | [197](/filings/0001048477-25-000107.md) | [196](/filings/0001048477-26-000008.md) | [197](/filings/0001048477-26-000016.md) | [192](/filings/0001048477-25-000107.md) | [198](/filings/0001048477-26-000008.md) | [194](/filings/0001048477-26-000016.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 193,573,759 at 2026-07-28, from the cover of the [10-Q filed 2026-08-06](/filings/0001048477-26-000016.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.